United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $236.47, for a total value of $851,292.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,741.10. The sale was disclosed in a filing with the SEC, which is available through this link.
United Therapeutics Price Performance
NASDAQ:UTHR traded up $0.41 during mid-day trading on Tuesday, hitting $234.47. 521,396 shares of the stock traded hands, compared to its average volume of 435,510. The business’s 50-day moving average price is $232.07 and its 200 day moving average price is $228.68. The company has a market cap of $11.03 billion, a PE ratio of 11.80 and a beta of 0.52. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same period in the prior year, the company earned $2.67 EPS. The company’s quarterly revenue was up 25.1% compared to the same quarter last year. On average, analysts expect that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on United Therapeutics
Institutional Trading of United Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth approximately $43,000. C M Bidwell & Associates Ltd. bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $91,000. Ronald Blue Trust Inc. boosted its stake in shares of United Therapeutics by 155.9% in the 3rd quarter. Ronald Blue Trust Inc. now owns 458 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 279 shares in the last quarter. Finally, Janiczek Wealth Management LLC raised its stake in shares of United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the last quarter. 94.08% of the stock is owned by institutional investors.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Insider Trading – What You Need to Know
- Lockheed Martin Stock Aims for a Fresh All-Time High
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.